Jeremy G Chadwick

COO Jeremy G Chadwick sells 17,184 shares totaling $1,373,289.54 at KYMR via 10b5-1 plan

Jeremy G Chadwick, Chief Operating Officer, executed 7 separate sales totaling 17,184 shares for $1,373,289.54 between May 26 and May 27, 2026, reducing his holdings by 28.1% (from 61,202 to 44,018 shares). This transaction is part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. In context of the company's fundamentals—annual revenue growth of -16.7%, net income of $-69,234,000.00 (unprofitable), and a current stock price of $81.70 that is -20.7% from the 52-week high—this sale represents a substantial reduction in his concentrated position. His prior trades at this ticker show consistent 30-day and 90-day negative returns, with the most recent sales on 2026-04-15 yielding -8.7% and -10.3% respectively, and earlier sales showing 30-day losses ranging from -5.0% to -6.2%.

COO Chadwick Jeremy G sold 6,551 shares at $90.00 over 2 days, reducing stake 9.7%

Chadwick Jeremy G, Chief Operating Officer of Kymera Therapeutics, executed 2 separate sales totaling 6,551 shares for $589,598.40 at a blended average price of $90.00 on April 14–15, 2026. His post-transaction holdings of 61,202 shares represent a 9.7% reduction from his prior position. The sales occurred at prices near the 52-week high of $95.03, following a strong 30-day gain of +6.1% and 90-day gain of +23.9%. Kymera is unprofitable with a full-year net income of $-82,175,000.00 and annual revenue that declined 16.7% year-over-year, though the stock has rallied significantly in recent months. His prior 5 trades at this ticker remain unmeasurable in their 90-day outcomes due to recent execution, limiting conclusive pattern analysis at the KYMR-specific level.

COO Chadwick Jeremy G sold 22,240 shares at $85.38–$86.05 over two days for $1.9M, reducing holdings by 26.7%

Chadwick Jeremy G, Chief Operating Officer, executed 3 separate sales totaling 22,240 shares for $1,900,047.90 (blended average price $85.43) on March 31 and April 1, 2026, reducing his stake from 83,442 shares to 61,202 shares. The magnitude—a 26.7% reduction in holdings over two trading days—is substantial for a C-suite executive. The company is unprofitable with net income of $-82,175,000.00 and annual revenue declining 16.7% year-over-year, representing a deteriorating financial backdrop. His prior trades at KYMR span 5 recent sales (all in March 2026), suggesting a pattern of liquidation activity coinciding with weak fundamentals; however, the 90-day return outcomes on those prior trades are not yet measurable, limiting assessment of execution quality at this specific ticker.

COO Chadwick Jeremy G sold 115,977 shares for $9,048,290.10 across 6 transactions on 2026-03-23 and 2026-03-25, reducing holdings by 65.5%.

Chadwick Jeremy G, Chief Operating Officer, executed 6 separate sales totaling 115,977 shares for $9,048,290.10, liquidating 65.5% of his pre-transaction holdings from 177,179 shares down to 61,202 shares. The sales occurred at prices ranging from $76.73 to $80.26 (blended average $78.02), near the current price of $78.93 but well below the 52-week high of $95.03. This large concentrated disposal by a C-suite executive comes as the company grapples with significant operational headwinds: revenue declined 16.7% year-over-year, the latest quarter showed only $2.8M in revenue alongside a $-82.2M net loss, and the stock has fallen 10.7% over the past 30 days and 5.0% over 90 days. The magnitude of the sale (two-thirds of holdings in rapid succession) represents material portfolio action by a senior executive at a company facing both revenue contraction and ongoing unprofitability.

COO Chadwick Jeremy G sold 25,758 shares across 3 trades for $2,145,673.35, reducing holdings 27.5% to 68,052 shares.

On 2026-03-11, COO Chadwick Jeremy G executed 3 separate sales totaling 25,758 shares for $2,145,673.35 at blended average price $83.30. This represents a -27.5% reduction in his post-transaction holdings from 93,810 shares to 68,052 shares. The current stock price of $81.52 is -14.2% from the 52-week high of $95.03, positioned just below the transaction prices achieved. The company reported -16.7% annual revenue growth and remains unprofitable with -$82,175,000.00 in net income over its most recent full fiscal year. Notably, the COO executed a series of sales on 2026-03-04 just one week prior (5 prior trades at KYMR within 7 days), suggesting a deliberate liquidation pattern rather than isolated portfolio activity.

COO Chadwick Jeremy G sold 5,958 shares (6.0K) for $515,594.12 across 7 transactions at blended avg $86.54.

Chadwick Jeremy G, Chief Operating Officer at Kymera Therapeutics, executed 7 separate sales totaling 5,958 shares for $515,594.12 on 2026-03-02 and 2026-03-04, reducing his holdings from 79.8K to 73.8K shares (-7.5%). The sale occurred near the 52-week high of $95.03, with the blended average price of $86.54 representing strong positioning relative to recent momentum (+13.9% over 30 days, +30.0% over 90 days). However, the company's financial condition is concerning: it reported quarterly revenue of $2.8M, net income of $-82.2M, annual revenue decline of -16.7%, and remains unprofitable. The COO's disposition of shares—while relatively modest as a percentage of post-transaction holdings (73.8K remaining)—occurs in the context of deteriorating operational performance and negative earnings trajectory, warranting attention to whether this reflects cash flow management or broader confidence pressures.